ICG uptake was not specific to tumor cells in a microscopy comparison of SCC026 carcinoma and HaCaT non-tumor skin cells. At 0.6 μg/ml, both cell lines showed living-cell uptake after 2.5 h, while dead cells showed uptake after 1 min. The study provides a qualitative limit on interpreting ICG fluorescence as selective tumor-cell labeling. [3]
Lipid-ratio dependence of ICG fluorescence
Biochemical assay · Cell-free DSPC:DSPEmPEG2000 (9:1 molar ratio) liposomes versus soluble ICG [1]
Fluorescence yield varied with lipid:ICG ratio. The 250:1 formulation gave the highest fluorescence per unit ICG among the eight tested ratios; increasing the ratio further did not continue to improve yield.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.01–2.0 μM ICG for fluorescence measurements; eight lipid:ICG ratios spanning 100:1–500:1
- Method
- Plate-reader fluorescence; excitation 769 ± 41 nm, emission 832 ± 37 nm
- Vehicle
- 0.9% NaCl, 20 mM NaHCO3 buffer, pH 7
- Co-treatment
- DSPC:DSPEmPEG2000 9:1 liposomal formulation; soluble ICG comparator
- Reported limits
- Measurement incubation duration not specified for this formulation comparison.
Methods and source locations
Compound reported in the paper: Indocyanine green; Compound label in the paper: Sigma-Aldrich ICG, sodium form (C43H47N2NaO6S2), free and lipid-incorporated
Supports formulation-dependent optical behavior; the catalog material is not a preformed liposome.
Experimental Procedures: Chemicals, Liposome Preparation, Fluorescence; Results: Incorporation of ICG into Lipid Membranes To Stabilize and Maximize ICG Fluorescence; Figure 3B–C
Highest fluorescence yield among tested formulations: Fluorescence intensity per μM ICG (slope); Figure 3B points mean ± SD, eight replicates; Figure 3C points mean ± SD, six replicates. — Figure 3B–C and caption; corresponding Results subsection
Storage-dependent loss of free and liposomal ICG fluorescence
Biochemical assay · Free ICG in buffer versus lipid-incorporated ICG at lipid:ICG 250:1 [1]
During dark storage at 4 °C, free ICG lost fluorescence much faster than the specific liposomal formulation. These are fluorescence-decay endpoints, not chemical-purity or catalog shelf-life measurements.
Literature-Reported Treatment Conditions
- Exposure duration
- Up to 313 days for liposomal ICG; free-ICG fit used five time points over 239 days; Table 1 reports 8-month fluorescence.
- Method
- Fluorescence measured during storage; exponential decay model
- Vehicle
- 0.9% NaCl, 20 mM NaHCO3 buffer, pH 7
- Co-treatment
- Liposomal arm: DSPC:DSPEmPEG2000 9:1, lipid:ICG 250:1; free ICG comparator
- Reported limits
- Storage-sample ICG concentration was not separately restated in the storage paragraph; 2.0 μM is explicitly given for the distinct light-exposure test and is not transferred here. No chemical degradation-product analysis supports these fluorescence endpoints.
Methods and source locations
Compound reported in the paper: Indocyanine green; Compound label in the paper: Sigma-Aldrich ICG sodium, free versus lipid-incorporated
Condition-specific fluorescence stability only; does not establish dry-powder shelf life.
Experimental Procedures: Light Exposure and Storage Stability; Results: Effects of Lipid Incorporation on Enhancing ICG Stability for Light Exposure and Storage; Figure 5; Table 1
Fluorescence retained at 8 months, relative to initial signal: Table 1: mean ± SD, N = 2 samples each at 8 months. Figure 5 time-course points have three to eight replicates. — Table 1, column % ICG fluorescence (8 months), footnotes a–b; Figure 5
Fitted half-life of fluorescence during dark storage at 4 °C: Exponential decay model. Liposomal fit: N = 10 time points over 313 days; free fit: N = 5 time points over 239 days; these N values are not animal/sample counts. — Table 1, t1/2 column and footnotes c–d; Figure 5
Qualitative ICG uptake in carcinoma and non-tumor cells
Cell-based study · Human squamous cell carcinoma SCC026 and immortalized non-cancer skin HaCaT cells [3]
Both cell lines showed uptake into living cells after 2.5 h; dead cells took up ICG earlier. The authors found no distinct tumor-cell-specific uptake in this model. Images used automatically chosen exposure times and do not establish equal uptake magnitudes.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.6 μg/ml ICG
- Exposure duration
- 1, 45 and 90 min, 2.5 and 24.0 h incubation
- Method
- ICG fluorescence microscopy with calcein AM/ethidium homodimer-1 live/dead staining; washes before imaging
- Vehicle
- Fresh cell growth medium containing ICG; SCC026: MEM with 20% fetal bovine serum and 2 mM L-glutamine; HaCaT: DMEM with 10% fetal bovine serum and 2 mM L-glutamine
- Co-treatment
- No therapeutic combination; live/dead stains used as markers. Matched cells without ICG underwent the same incubation/staining.
- Reported limits
- Biological replicate count and quantitative uptake statistics not stated in selected cell-culture methods/results. No-ICG control/cell-survival results are described as data not shown.
Methods and source locations
Compound reported in the paper: Indocyanine green; Compound label in the paper: ICG (Verdye, Diagnostic Green GmbH)
Qualitative uptake and selectivity limitation for the named formulation and models.
Materials and methods: Fluorescence microscopy; Results: ICG imaging of cell cultures; Figure 1A–C and caption; Discussion
Timing of detectable cellular ICG signal: Figure 1A–B; live/dead staining. Earlier time-course absence is reported in Results as data not shown. No signal intensities estimated from images. — Results: ICG imaging of cell cultures; Figure 1A–B and caption
Partial inhibition of cellular ICG uptake by Pitstop 2
Cell-based study · HT-1080 human sarcoma cells [2]
Pitstop 2 pretreatment reduced intracellular ICG fluorescence in the microscopy assay relative to ICG alone and the Pitstop 2 negative-control compound. Uptake was not fully suppressed to the no-ICG baseline. The authors note that Pitstop 2 has only partial endocytosis-pathway selectivity, limiting attribution to clathrin alone.
Literature-Reported Treatment Conditions
- Treatment concentration
- ICG 25 μM; Pitstop 2 5–30 μM or negative-control compound 30 μM
- Exposure duration
- Inhibitor pretreatment for 15 min, followed by ICG for 30 min in continued inhibitor presence
- Method
- Fluorescence microscopy, main Figure 4; ICG excitation 670–745 nm and emission 768–850 nm; DAPI nuclear counterstain
- Vehicle
- Serum-free DMEM/F-12 with 15 mM HEPES; inhibitor solutions described as containing 0.1% DMSO before ICG addition
- Co-treatment
- Pitstop 2 or structurally related inactive negative-control compound; ICG-only and no-ICG controls shown in Figure 4.
- Reported limits
- Final DMSO fraction after ICG addition is not separately specified. Biological replicate count for Figure 4 is not stated in the read main-text methods/caption. Supplementary details not retrieved due access challenge.
Methods and source locations
Compound reported in the paper: Indocyanine green; Compound label in the paper: Clinical-grade ICG (Verdye, Diagnostic Green), lyophilized powder
Evidence for a Pitstop-sensitive component of cellular uptake under the stated conditions; insufficient to establish exclusive clathrin-mediated uptake or tumor selectivity.
Materials and methods: Fluorescent agents, Cell culture, Inhibition of clathrin-mediated endocytosis, Fluorescence microscopy, Image quantification; Results: Inhibition of clathrin-mediated endocytosis reduces ICG cellular uptake; Figure 4A–B and caption; Discussion
Mean ICG fluorescence intensity per cell after inhibitor pretreatment: 40× microscopy images quantified per cell using DIC-guided polygonal outlines in ZEN Blue v3.3. Figure 4B values shown with 95% CI. Exact effect sizes and replicate counts not inferred. — Materials and methods: Fluorescent agents, Cell culture, Inhibition of clathrin-mediated endocytosis, Fluorescence microscopy, Image quantification; Results: Inhibition of clathrin-mediated endocytosis reduces ICG cellular uptake; Figure 4A–B and caption; Discussion